Rational, biologically based treatment of EGFR mutant non small cell lung cancer
Epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The disease has been the subject of intensive research at both the basic scientific and clinical levels, becoming a paradigm for how to understand and treat oncogene driven carcinomas. Although patients with EGFR mutant tumours have increased sensitivity to tyrosine kinase inhibitors (TKIs) primary and acquired resistance to these agents remains a major clinical problem. This Review summarizes recent developments aimed at treating and ultimately curing the disease.
Nature Reviews Cancer